ASX:CSL
ASX:CSLBiotechs

CSL (ASX:CSL) Secures NICE Approval For Sparsentan Use In NHS England

CSL (ASX:CSL) saw its stock price rise by 3% over the last month, amid important developments and a fluctuating market environment. CSL Vifor's notable progress with the National Institute for Health and Care Excellence recommending sparsentan for primary IgA nephropathy treatment may have provided positive momentum. This significant medical endorsement, alongside CSL's continued engagement with shareholders through meetings, could have added weight to its share performance. Meanwhile,...
ASX:CQR
ASX:CQRRetail REITs

Exploring 3 Undervalued Small Caps In Global With Insider Action

As global markets react positively to the recent U.S.-China tariff suspension, with major indices like the Nasdaq Composite and S&P 500 showing significant gains, small-cap stocks have also benefited from this improved sentiment. In this environment of easing trade tensions and cooling inflation, identifying promising small-cap stocks involves looking for those with strong fundamentals and potential insider action that may signal confidence in their future growth.